Bond.az White LogoBond.az Black Logo

Citizens Raises Rithm Capital Price Target

Citizens raises Rithm Capital price target to $13.50, highlighting asset growth and a shift to asset management. RITM offers a 11.11% dividend yield.

Mia Lopez
ByMia Lopez- Senior Editor
|
0

Citizens raised its price target on Rithm Capital Corp. (NYSE:RITM) to $13.50 from $12.50 while maintaining a Market Outperform rating. The stock currently trades at $9, suggesting significant upside potential.

The firm established co-coverage between its Mortgage Finance and Alternative Asset Management research teams. Rithm acquired Sculptor Capital Management in late 2023, marking a move into alternative asset management.

Later, the company became the external manager of publicly traded mortgage REIT Rithm Property Trust and acquired Crestline Management in late 2025. Rithm's asset management segment now has $59 billion in assets under management.

Mortgage origination and servicing remains the largest segment at roughly 45% of equity. Asset management is second at 18%, followed by commercial real estate at 18%, the investment portfolio at 12%, and the Genesis residential transition loan business at 7%. Notably, the company offers an exceptional 11.11% dividend yield and has paid dividends for 14 consecutive years.

Citizens said the co-coverage is appropriate given management's strategic focus on asset management. Rithm Capital recently reported Q1 2026 earnings that surpassed expectations, with EPS of $0.51 versus $0.50 forecast, and revenue of $1.38 billion against $1.25 billion expected.

More News
Today / 09:00
|
268

Citizens Raises Relay Price Target to $21

Citizens raises Relay Therapeutics price target to $21 on strong trial data for zovegalisib, with shares up 296%.

0
Today / 08:32
|
341

Raymond James Upgrades SM Energy on Oil Strength

Raymond James upgrades SM Energy to Outperform with $55 target on oil strength. SM Energy benefits from Iran war oil price surge.

0
Today / 08:21
|
408

Jefferies Initiates SAB Biotherapeutics with Buy

Jefferies initiates coverage on SAB Biotherapeutics with a Buy rating and $11 target, focusing on SAB-142 diabetes therapy.

0
Today / 08:03
|
826

UBS Upgrades Packaging Corp. Stock Rating

UBS upgraded Packaging Corp. of America from Neutral to Buy, raising price target to $248. Learn more about PKG stock on Bond.az.

0
Today / 08:02
|
746

BofA Maintains Buy on MakeMyTrip, $60 Target

BofA Securities reiterates Buy on MakeMyTrip (MMYT) with $60 target due to margin expansion and cost control in Q4 results.

0
Today / 07:55
|
540

RBC Capital Cuts Home Depot Target on Housing Woes

RBC Capital cuts Home Depot price target to $340 on housing concerns and higher interest rate outlook. Stock trades near 52-week low.

0
Today / 07:54
|
619

Cantor Fitzgerald Initiates X-Energy with Overweight

Cantor Fitzgerald starts X-Energy with Overweight rating and $38 target, citing strategic position in advanced nuclear.

0
Today / 07:15
|
450

Jefferies downgrades Lanxess stock rating

Jefferies downgraded Lanxess to Underperform with a EUR16 target. Stock at $20.04. Weak chemicals market, Iran conflict impact, and demand risks ahead.

0
Yesterday / 20:01
|
493

Relay Therapeutics Stock Upgrade Boosts Price

Relay Therapeutics stock upgraded by Jones Trading to Buy with $20 target after positive zovegalisib trial data.

0
Yesterday / 19:51
|
929

SandRidge Energy Stock Rating Upgraded to Hold

Freedom Broker upgraded SandRidge Energy to Hold after strong Q1 2026 results. Dividend increased by 8.3% to $0.13 per share.

0
Yesterday / 19:30
|
676

Inuvo PT Cut to $2.50 After Weak Q1

Freedom Broker cut Inuvo's price target to $2.50 after weak Q1 results. Stock fell 20% as the company transitions to IntentKey AI platform. Analysts predict profitability this year.

0
Yesterday / 18:51
|
524

CoreWeave Stock Rises on AI Demand Outlook

Evercore ISI reaffirms Outperform for CoreWeave. AI demand drives positive outlook for the company.

0
...